Migraine attack incidence in relation to the post-ovulatory estrogen decline: A prospective cohort study

BackgroundPrevious studies suggest the perimenstrual phase increases migraine without aura risk, attributed to the decline of estrogen in this phase. However, the link to the decline of estrogen in the post-ovulatory phase remains unclear.MethodsWe conducted a longitudinal cohort study among 563 women with migraine and a regular natural menstrual cycle. Participants completed a validated e-headache diary also including menstrual cycle tracking. Of these women, 31 (who participated in our Women Hormones Attacks and Treatment (WHAT)-hormone study) performed urine luteinizing hormone (LH) surge tests during two menstrual cycles to validate the estimation of the post-ovulatory estrogen decline. The association between the post-ovulatory estrogen decline and migraine incidence was assessed using a mixed logistic model with patient as random effect, and the post-ovulatory and menstrual window as fixed effects. Secondary analyses included a case-crossover model and a self-controlled case series (SCCS) model to strengthen robustness and control for time-invariant confounders.ResultsE-diary data from 2627 menstrual cycles, including 58 from the WHAT-hormone subgroup, were analyzed. Across all three statistical models, the post-ovulatory window showed no higher incidence of migraine (with or without aura) than other menstrual cycle days (mixed logistic model: OR 0.95, 95% CI 0.89-1.02; WHAT-hormone subgroup: OR 0.68, 95% CI 0.38-1.16). The perimenstrual window had the highest migraine incidence (SCCS model with luteal phase as reference: OR 1.67, 95% CI 1.60-1.75), followed by the follicular phase (OR 1.31, 95% CI 1.26-1.37).DiscussionIn contrast to what many women with migraine believe, there is no increased incidence of migraine attacks (with or without aura) during the post-ovulatory window, but a higher incidence during the follicular phase compared to the luteal phase was confirmed.

Authors

Institutions

Publication Details

Journal
Cephalalgia
Published
2026-04-01
DOI
https://doi.org/10.1177/03331024261436415
Primary Topic
Migraine and Headache Studies
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Migraine attack incidence in relation to the post-ovulatory estrogen decline: A prospective cohort study

Daphne S. van Casteren, Nadine Pelzer, I. De Boer, Suzanne C. Cannegieter et al.
Cephalalgia
Migraine and Headache Studies
article

Migraine attack incidence in relation to the post-ovulatory estrogen decline: A prospective cohort study

Daphne S. van Casteren, Nadine Pelzer, I. De Boer, Suzanne C. Cannegieter, Iris E. Verhagen, Gisela M. Terwindt, Britt W.H. van der Arend, Sally Bakker, Antoinette MaassenVanDenBrink
article en

Abstract

BackgroundPrevious studies suggest the perimenstrual phase increases migraine without aura risk, attributed to the decline of estrogen in this phase. However, the link to the decline of estrogen in the post-ovulatory phase remains unclear.MethodsWe conducted a longitudinal cohort study among 563 women with migraine and a regular natural menstrual cycle. Participants completed a validated e-headache diary also including menstrual cycle tracking. Of these women, 31 (who participated in our Women Hormones Attacks and Treatment (WHAT)-hormone study) performed urine luteinizing hormone (LH) surge tests during two menstrual cycles to validate the estimation of the post-ovulatory estrogen decline. The association between the post-ovulatory estrogen decline and migraine incidence was assessed using a mixed logistic model with patient as random effect, and the post-ovulatory and menstrual window as fixed effects. Secondary analyses included a case-crossover model and a self-controlled case series (SCCS) model to strengthen robustness and control for time-invariant confounders.ResultsE-diary data from 2627 menstrual cycles, including 58 from the WHAT-hormone subgroup, were analyzed. Across all three statistical models, the post-ovulatory window showed no higher incidence of migraine (with or without aura) than other menstrual cycle days (mixed logistic model: OR 0.95, 95% CI 0.89-1.02; WHAT-hormone subgroup: OR 0.68, 95% CI 0.38-1.16). The perimenstrual window had the highest migraine incidence (SCCS model with luteal phase as reference: OR 1.67, 95% CI 1.60-1.75), followed by the follicular phase (OR 1.31, 95% CI 1.26-1.37).DiscussionIn contrast to what many women with migraine believe, there is no increased incidence of migraine attacks (with or without aura) during the post-ovulatory window, but a higher incidence during the follicular phase compared to the luteal phase was confirmed.

CephalalgiaVol. 46(4)
Leiden University Medical Center (NL), Erasmus University Rotterdam (NL)
Amgen, Eli Lilly and Company, Pfizer, Teva Pharmaceutical Industries, Nederlandse Organisatie voor Wetenschappelijk Onderzoek, Hersenstichting, Stichting Dioraphte, H. Lundbeck A/S
Good health and well-being, Gender equality
Openalex Percentile: Top 29%
Migraine and Headache Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.